Sera Prognostics Company

Sera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans. The company has completed its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study that clinically validated the PreTRM test as highly predictive of preterm birth early in pregnancy. the PreTRM test detects protein levels in blood that are highly predictive of premature birth.
Technology: Longevity FemTech
Industry: Biotechnology, Health Care, Hospital, Medical, Medical Device
Headquarters: Salt Lake City, Utah, United States
Founded Date: 2008
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 8
Total Funding: $150.3M
Estimated Revenue: $10M to $50M
Last Funding Type: Series D

Visit Website
info@seraprognostics.com
Register and Claim Ownership